icer orphan drug assessment and pricing summit - part 2 of 3
Published 7 years ago • 280 plays • Length 1:26:30Download video MP4
Download video MP3
Similar videos
-
2:27:50
icer orphan drug assessment and pricing summit - part 3 of 3
-
1:49:07
icer orphan drug assessment and pricing summit - part 1 of 3
-
4:04
the first take: icer drug pricing reviews - what's next and what impact?
-
1:03:24
icer valuing a cure meeting: questions about additional elements of value
-
1:26:55
icer valuing a cure meeting: affordability and fair sharing of economic surplus
-
4:36
week 9 video 2: cost effectiveness, icer and acer
-
6:41
orphan drugs: an introduction
-
7:54
2. cea approach and icers
-
2:04
what's wrong with icer?
-
1:07:13
icer's updated value assessment framework
-
2:04:15
icer midwest cepac public meeting on amyotrophic lateral sclerosis (als): policy roundtable
-
1:01:02
icer’s value assessment framework: an overview of the 2020 value framework
-
2:54
limitations of icer’s value assessment framework tool
-
6:13
access & pricing of orphan drugs
-
1:01:25
ctaf, osteoporosis - june 30, 2017 (voting)
-
1:15:38
ne cepac: evidence presentation, opioid use disorder
-
9:12
orphan drug development | episode 01- what is orphan drug? | rare disease | drug regulatory affairs
-
1:33:56
i3h seminar: budget impact analysis and payment approaches for orphan drugs
-
1:03:23
duke neurology grand rounds, february 9, 2022: gordon smith, md
-
35:39
new england cepac: public comments, spinal muscular atrophy
-
56:56
orphan drugs: making rare disease rarer
-
1:08:01
panel 1: defining & assessing drug value (unpacking drug value) | kaiser permanente